Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01911065 · ClinicalTrials.gov registry record · Phase 4
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
NCT01911065: Completed Phase 4 study, sponsored by Stanford University.
NCT01911065 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01911065, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
Study Summary
In this study the investigators are trying to identify immune signatures that are associated with effective or poor vaccine responses to naturally-acquired herpes zoster virus and the zoster (shingles) vaccine, Zostavax.
Interventions
- BIOLOGICAL Zostavax™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01911065
The ClinicalTrials.gov registry entry for NCT01911065 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zostavax™ is the first listed.
NCT01911065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01911065 about?
NCT01911065 is a clinical study titled "T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020". In this study the investigators are trying to identify immune signatures that are associated with effective or poor vaccine responses to naturally-acquired herpes zoster virus and the zoster (shingles) vaccine, Zostavax.
What is the current status of trial NCT01911065?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2010-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01911065?
The interventions under investigation include: Zostavax™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT01911065?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.